Remove Environment Remove Pharmaceutical Remove Policy
article thumbnail

NCIA Policy Report: The Medicine of Cannabis: An Overview for Medical Professionals and Policymakers

Cannabis Law Report

Prepared by NCIA’s Policy Council. Patients are looking to their medical providers for information on cannabis safety, potential for interactions with pharmaceuticals, and therapeutic applications. cannabis policy are needed, particularly at the federal level. As cannabis use expands in the U.S., Download at [link].

Policy 105
article thumbnail

Australia Cannabis Q&A

Canna Law Blog

Can businesses cultivate cannabis for pharmaceutical research? Employers should: Establish fair and transparent testing policies. Can employers enforce a zero-tolerance cannabis policy? Businesses should ensure written policies are consistent with relevant state and federal employment law.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Sale of CBD Foods Is Legal in the UK (For Now)

Canna Law Blog

Although the UK recently severed its ties with the European Union, the FSA has opted to align its policy with that of the European Food Safety Authority (“ EFSA ”). Following the March 31, 2021 deadline, only products for which a valid application has been submitted will be allowed to remain on the market.

Food 127
article thumbnail

Not-very-NICE: UK Cannabis Policy and Harm to Patients

CannaTech

The supportive regulatory environment has facilitated a mounting body of clinical and transnational research demonstrating the efficacy of medically prescribed marijuana. UK cannabis policy is not serving the interests of patients. The post Not-very-NICE: UK Cannabis Policy and Harm to Patients appeared first on Canna Tech Global.

article thumbnail

New Publication: NCIA’s Policy Council – The Medicine of Cannabis: An Overview for Medical Professionals and Policymakers

Cannabis Law Report

Patients are looking to their medical providers for information on cannabis safety, potential for interactions with pharmaceuticals, and therapeutic applications. However, the existing legal environment significantly hinders the ability of clinicians to engage with cannabis research or offer clear guidance. Download at [link].

Policy 61
article thumbnail

The Psilocybin Movement is Like the Cannabis Movement (Except When It’s Not)

Canna Law Blog

The second track for psilocybin is the pharmaceutical model. This type of proposal envisions psilocybin-assisted therapy in controlled environments. On the pharmaceutical side, the FDA’s willingness to grant breakthrough therapy status to psychedelic drugs, as mentioned above, has put psilocybin approvals in an expeditious place.

article thumbnail

Zimbabwe Govt Offers New Guarantees and Incentives for Cannabis Investors & Establishes Green Industry Fund

Cannabis Law Report

The Harare government has also approved the establishment of the Green Industry Fund, to promote local beneficiation, skills transfer and development of the local pharmaceutical industry. 100% foreign ownership a ‘significant departure from previous policy’.

Medicine 105